Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Andrea CALCAGNO; Ivano Dal Conte; Dario Cattaneo; Roberto Testi; Massimiliano Mistrangelo; Cristina Gervasoni; Amedeo de Nicolò; Stefano Bonora; Antonio D'Avolio; Giovanni Di Perri

doi:10.1128/AAC.01902-20

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Andrea CALCAGNO, Ivano Dal Conte, Dario Cattaneo, Roberto Testi, Massimiliano Mistrangelo, Cristina Gervasoni, Amedeo de Nicolò, Stefano Bonora, Antonio D'Avolio, Giovanni Di Perri

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

Lingua originale	Inglese
pagine (da-a)	e01902-20-e01902-20
Numero di pagine	5
Rivista	Antimicrobial Agents and Chemotherapy
Volume	65
Numero di pubblicazione	1
DOI	https://doi.org/10.1128/AAC.01902-20
Stato di pubblicazione	Pubblicato - 2021

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1128/AAC.01902-20

https://hdl.handle.net/11579/216866

Altri file e collegamenti

handle

Cita questo

@article{5070f74862ce4be580274e3697d913ce,

title = "Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders",

abstract = "Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.",

author = "Andrea CALCAGNO and \{Dal Conte\}, Ivano and Dario Cattaneo and Roberto Testi and Massimiliano Mistrangelo and Cristina Gervasoni and \{de Nicol{\`o}\}, Amedeo and Stefano Bonora and Antonio D'Avolio and \{Di Perri\}, Giovanni",

year = "2021",

doi = "10.1128/AAC.01902-20",

language = "English",

volume = "65",

pages = "e01902--20--e01902--20",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

TY - JOUR

T1 - Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

AU - CALCAGNO, Andrea

AU - Dal Conte, Ivano

AU - Cattaneo, Dario

AU - Testi, Roberto

AU - Mistrangelo, Massimiliano

AU - Gervasoni, Cristina

AU - de Nicolò, Amedeo

AU - Bonora, Stefano

AU - D'Avolio, Antonio

AU - Di Perri, Giovanni

PY - 2021

Y1 - 2021

N2 - Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

AB - Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

UR - https://iris.uniupo.it/handle/11579/216866

U2 - 10.1128/AAC.01902-20

DO - 10.1128/AAC.01902-20

M3 - Article

SN - 0066-4804

VL - 65

SP - e01902-20-e01902-20

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 1

ER -

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo